WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555217
CAS#: 173528-92-2
Description: HMN-154 is a benzenesulfonamide anticancer agent. HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner.
MedKoo Cat#: 555217
Name: HMN-154
CAS#: 173528-92-2
Chemical Formula: C20H18N2O3S
Exact Mass: 366.1038
Molecular Weight: 366.435
Elemental Analysis: C, 65.56; H, 4.95; N, 7.65; O, 13.10; S, 8.75
Synonym: HMN-154; HMN 154; HMN154.
IUPAC/Chemical Name: (E)-4-(2-(2-(N-(4-Methoxybenzenesulfonyl)amino)phenyl)ethenyl)pyridine
InChi Key: CIJCDFMGZYKSSC-VOTSOKGWSA-N
InChi Code: InChI=1S/C20H18N2O3S/c1-25-18-8-10-19(11-9-18)26(23,24)22-20-5-3-2-4-17(20)7-6-16-12-14-21-15-13-16/h2-15,22H,1H3/b7-6+
SMILES Code: O=S(NC1=CC=CC=C1/C=C/C2=CC=NC=C2)(C3=CC=C(OC)C=C3)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively. |
| In vitro activity: | Furthermore, HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner. Reference: Mol Pharmacol. 1999 Feb;55(2):356-63. https://pubmed.ncbi.nlm.nih.gov/9927629/ |
| In vivo activity: | TBD |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 15.0 | 40.93 |
The following data is based on the product molecular weight 366.435 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63. doi: 10.1124/mol.55.2.356. PMID: 9927629. |
| In vitro protocol: | 1. Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63. doi: 10.1124/mol.55.2.356. PMID: 9927629. |
| In vivo protocol: | TBD |
1: Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular
drug-binding proteins using a novel expression cloning procedure: drug-western.
Mol Pharmacol. 1999 Feb;55(2):356-63. PubMed PMID: 9927629.
